Parkinson's Vax Enters Clinical Trials

Researchers in Vienna are starting a Phase I trial on the first ever vaccine with a potential to treat the neurodegenerative disease.

By | June 7, 2012

Alpha-synuclein accretions (brown spots) accumulate in the brains of Parkinson's patientsWikimedia Commons, Jensflorian

Alpha-synuclein accretions (brown spots) accumulate in the brains of Parkinson's patients WIKIMEDIA COMMONS, JENSFLORIAN

A new vaccine that has the potential to treat Parkinson's disease is entering a Phase I clinical trial in Vienna. The first-of-its-kind vaccine, PD01A, aims to ramp up an immune response to the alpha-Synuclein (alpha-syn) protein, which is involved in the onset and progression of Parkinson's. Austrian biotech AFFiRiS is testing the vaccine with support from the Michael J. Fox Foundation.

"Worldwide, for the first time immunotherapy is applied for the treatment of Parkinson's," AFFiRiS CEO Walter Schmidt said in a statement. "PD01A is the first medication worldwide aiming for clinical efficacy by modulating the metabolic pathway of alpha-syn."

Hat tip to Medical News Today.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Antarctica Is Turning Green
  2. How to Tell a Person’s “Brain Age”
  3. Male Fish Borrows Egg to Clone Itself
  4. Life Science Funding Cuts Leaked
    The Nutshell Life Science Funding Cuts Leaked

    According to a document posted online less than a day before the release of the official 2018 budget proposal, the National Institutes of Health could face even deeper cuts than previously suggested by the Trump administration.

AAAS